Ocular drug dispensing system

Claim 2

An ocular delivery device for the continuous administration of drug over a prolonged period of time comprising a sealed container shaped for insertion into the eye, the container having a pair of first and third membrane walls spaced from each other, each formed of a material insoluble in tear fluid, with at least one of the membrane walls being permeable to the passage of drug by diffusion at a controlled rate, and a second ring-shaped wall interposed between and sealingly engaging the first and third membrane walls along their outer faced peripheries to define an integral unit and form a reservoir defined by the inner surfaces of the first, second and third walls, said reservoir containing drug which is released therefrom at a controlled rate by passage through the rate controlling membrane wall.

Claim 3

An ocular drug dispensing device in accordance with claim 1 wherein said one wall that is permeable to the drug by diffusion at a predetermined rate is formed of a substantially homogenous and substantially imperforate polymeric material.

Claim 4

An ocular drug dispensing device in accordance with claim 1 wherein the first and third walls are both permeable to the drug by diffusion at a predetermined rate.

Claim 5

An ocular drug dispensing device in accordance with claim 1 wherein said one wall that is permeable to the drug at a predetermined rate is formed of a microporous polymeric material, the pores of which contain a medium in which the drug has limited solubility and which is permeable to the drug at the predetermined rate.

Claim 6

An ocular drug dispensing device in accordance with claim 1 wherein the second wall is formed of a cold setting adhesive, polymeric material.

Claim 7

An ocular drug dispensing device in accordance with claim 1 wherein the second wall is formed of a hot setting adhesive, polymeric material.

Claim 8

An ocular drug dispensing device in accordance with claim 1 wherein the second wall has a dye incorporated in it which makes its color distinct from the colors of the first and third walls.

Claim 9

An ocular drug dispensing device in accordance with claim 1 wherein the first and third walls are formed of ethylene-vinyl acetate copolymer.

Claim 10

An ocular device for the continuous administration of drug at a controlled rate over a prolonged period of time comprising a three-layered laminate having a pair of separate and discrete first and third walls formed of a material insoluble in tear fluid with at least one of the walls drug release rate controlling and permeable to the passage of drug by diffusion, a second wall interposed between the first and third walls and formed with an inwardly disposed hole with the second wall sealingly engaging the first and third walls to form a reservoir containing a drug, and wherein drug is administered from the device at a controlled rate by passage through the rate controlling wall.

Claim 11

An ocular device for the continuous administration of drug at a controlled rate over a prolonged period of time comprising a three-layered laminate having a pair of separate and discrete first and third walls formed of a material insoluble in tear fluid with at least one of the walls drug release rate controlling and permeable to the passage of drug by diffusion, a second wall interposed between the first and third walls and formed with an inwardly disposed hole with the second wall sealingly engaging the first and third walls to form a reservoir containing a drug, and wherein drug is administered from the device at a controlled rate by passage through the rate controlling wall.

Claim 12

An ocular device for the continuous administration of drug at a controlled rate for a prolonged period of time according to claim 9 wherein both the first and third walls are formed of a homogenous release rate controlling material permeable to the passage of drug by diffusion.

Claim 13

An ocular device for the continuous administration of drug at a controlled rate for a prolonged period of time according to claim 9 wherein the first wall is formed of a homogenous material permeable to the passage of drug and the third wall is formed of a material substantially impermeable to drug.

Claim 14

An ocular device for the continuous administration of drug at a controlled rate for a prolonged period of time according to claim 9 wherein the second wall interbonds the first and third walls around their faced margins with the second wall formed of a flexible, substantially imperforate material insoluble in tear fluid.

Claim 15

An ocular device for the continuous administration of drug at a controlled rate for a prolonged period of time according to claim 9 wherein the reservoir contains a composition comprising a drug and a carrier which carrier is more permeable to drug than is the rate-controlling wall.

Claim 16

An ocular device for the continuous administration of drug at a controlled rate for a prolonged period of time according to claim 9 wherein the device is shaped and sized for insertion and comfortable placement in the cul-de-sac of the eye.

Claim 17

An ocular device for the continuous administration of drug at a controlled rate for a prolonged period of time according to claim 9 wherein the rate-controlling walls are formed of ethylene-vinyl acetate copolymer.

Claim 18

An ocular device for the continuous administration of drug at a controlled rate for a prolonged period of time according to claim 9 wherein the reservoir contains a solid or gel composition comprising a drug and carrier shaped and sized to correspond to the dimensions of the reservoir.

Claim 19

An ocular device for the continuous administration of drug at a controlled rate for a prolonged period of time according to claim 16 wherein the carrier is a gellation agent.

Claim 20

An ocular device for the continuous administration of drug at a controlled rate for a prolonged period of time according to claim 17 wherein the agent is a polysaccharide.

Claim 21

An ocular device for the continuous administration of drug at a controlled rate for a prolonged period of time according to claim 9 wherein the reservoir contains alginic acid.

Claim 22

An ocular device for the continuous administration of drug at a controlled rate for a prolonged period of time according to claim 19 wherein the reservoir also contains pilocarpine and the ratio of pilocarpine to alginic acid is from 12 to 1.

Claim 23

A process for making a drug delivery device for dispensing drug at a predetermined rate for a prolonged period of time comprising: a. forming a first wall from a material insoluble in tear fluid and optionally permeable to drug at a predetermined rate; b. forming a second wall from a material insoluble in tear fluid in a ring shape having an outer perimeter of generally the same shape as the perimeter of the first wall; c. placing the second wall on the first wall with the outer perimeter of the second wall in general registry with the perimeter of the first wall; d. charging drug onto the surface of the first wall in the reservoir area thereof bounded by the inner perimeter of the second wall; e. forming a third wall from a material insoluble in eye fluid and optionally permeable to drug at a predetermined rate, with the proviso that at least one of the first and third walls is permeable to drug at a predetermined rate, in the same general shape as the first wall; f. placing the third wall over the drug with its perimeter in general registry with the outer perimeter of the second wall and its periphery contacting said second wall; and g. sealing the first and third walls to the second wall.

Claim 24

A process for making a drug delivery device for dispensing drug at a predetermined rate for a prolonged period of time comprising: a. forming a first wall from a material insoluble in tear fluid and optionally permeable to drug at a predetermined rate; b. forming a second wall from a material insoluble in tear fluid in a ring shape having an outer perimeter of generally the same shape as the perimeter of the first wall; c. placing the second wall on the first wall with the outer perimeter of the second wall in general registry with the perimeter of the first wall; d. charging drug onto the surface of the first wall in the reservoir area thereof bounded by the inner perimeter of the second wall; e. forming a third wall from a material insoluble in eye fluid and optionally permeable to drug at a predetermined rate, with the proviso that at least one of the first and third walls is permeable to drug at a predetermined rate, in the same general shape as the first wall; f. placing the third wall over the drug with its perimeter in general registry with the outer perimeter of the second wall and its periphery contacting said second wall; and g. sealing the first and third walls to the second wall.

Claim 25

A process in accordance with claim 21 wherein the first and third walls are heat sealed to the second wall.

Claim 26

A process in accordance with claim 21 wherein the second wall is formed of a cold setting adhesive polymeric material and the first and third walls are heat sealed to the second wall at 5°C to 50°C.

Claim 27

A process in accordance with claim 21 wherein the second wall is formed of a hot setting adhesive polymeric material and the first and third walls are heat sealed to the second wall at 50°C to 250°C.

Claim 28

A process in accordance with claim 21 wherein the first and second walls are formed from polymeric materials permeable to the drug at different, predetermined rates.

Claim 29

A process in accordance with claim 21 wherein the second wall is of a color which distinguishes it from the first and third walls.

Claim 30

A process in accordance with claim 21 wherein the drug delivery device is an ocular device in a shape and size adapted for insertion in a cul-de-sac of the eye.

Claim 31

A process in accordance with claim 21 wherein the drug is initially of a liquid character and is reacted or mixed with a gelling agent to form a gelled composition prior to charging the formulation onto the surface of the first wall in step (d) of said process.

Claim 32

A process in accordance with claim 28 wherein the gellation agent is agar, alginic acid, carrageenan, laminaran, tragacanth, gum arabic or gum ghatti.

Claim 33

A process in accordance with claim 28 wherein the drug is pilocarpine and the gelling agent is alginic acid.